Stockscreener 앱 받기
1.42
0.71%
0.01
시간 외 거래:
1.42
Acrivon Therapeutics Inc 주식(ACRV)의 최신 뉴스
Piper Sandler sets $6 target for Acrivon stock, rates it Overweight By Investing.com - Investing.com South Africa
Piper Sandler sets $6 target for Acrivon stock, rates it Overweight - Investing.com Australia
Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Shares Sold by JPMorgan Chase & Co. - Defense World
Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) PT at $21.80 - Defense World
Cantor Fitzgerald Has Positive View of ACRV FY2025 Earnings - Defense World
Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Decreases By 19.9% - Defense World
Acrivon Therapeutics’ major shareholder sells shares worth $1.02 million By Investing.com - Investing.com Canada
Major Shareholder Sells Massive Stake in Acrivon Therapeutics! - TipRanks
Acrivon Therapeutics’ major shareholder sells shares worth $1.02 million - Investing.com
You might want to take a look at Acrivon Therapeutics Inc (ACRV) now - Sete News
Acrivon Therapeutics Inc (ACRV)’s stock decline to 1.44 per share - uspostnews.com
Major Shareholder Sells Millions in Acrivon Therapeutics Stock! - TipRanks
ACRV’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Acrivon Therapeutics (ACRV) Sees Surge in Interest Amid Key Deve - GuruFocus
KeyBanc Capital Markets initates Acrivon Therapeutics Inc (ACRV) rating to an Overweight - knoxdaily.com
Understanding ACRV stock ratios for better investment decisions - uspostnews.com
Acrivon Therapeutics Presents Findings on ACR-2316's Mechanisms of Tumor Cell Death at AACR Annual Meeting - Nasdaq
Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 - GlobeNewswire
Breakthrough Cancer Drug ACR-2316 Achieves 25% Tumor Reduction with Zero Safety Issues in Phase 1 Trial - Stock Titan
Acrivon Therapeutics (ACRV) to Present Promising ACR-2316 Data at AACR Annual Meeting | ACRV Stock News - GuruFocus
(ACRV) On The My Stocks Page - news.stocktradersdaily.com
April 2025's Standout Penny Stocks - simplywall.st
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 21.4% in March - Defense World
Acrivon Therapeutics Inc’s Banking’s 100-Day Moving Average at 5.3600: Will the Stock Break Through? - investchronicle.com
ACRV’s price-to-cash ratio: How it affects the stock’s valuation. - uspostnews.com
Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV) - NewsBreak: Local News & Alerts
Acrivon Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal moment - Investing.com UK
Acrivon Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal moment By Investing.com - Investing.com South Africa
Acrivon Therapeutics’ SWOT analysis: oncology innovator’s stock faces pivotal moment - Investing.com India
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.17 Average Price Target from Analysts - Defense World
Acrivon Therapeutics Reports Progress in Cancer Drug Development - TipRanks
Acrivon Therapeutics Appoints Mansoor Raza Mirza, M.D., as Chief Medical Officer - citybiz
Acrivon appoints new chief medical officer to advance cancer trials By Investing.com - Investing.com South Africa
Acrivon Therapeutics Appoints Mansoor Mirza as Medical Chief - marketscreener.com
Acrivon appoints new chief medical officer to advance cancer trials - Investing.com
Acrivon Therapeutics Appoints New Chief Medical Officer - TipRanks
Acrivon Therapeutics Appoints World-Renowned Oncology Key - GlobeNewswire
Head-To-Head Comparison: Astellas Pharma (OTCMKTS:ALPMY) versus Acrivon Therapeutics (NASDAQ:ACRV) - The AM Reporter
Q1 Earnings Forecast for ACRV Issued By HC Wainwright - Defense World
Acrivon Therapeutics (NASDAQ:ACRV) and Astellas Pharma (OTCMKTS:ALPMY) Head to Head Contrast - Defense World
H.C. Wainwright maintains Acrivon stock Buy rating, $19 target By Investing.com - Investing.com Australia
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know - MSN
Acrivon Therapeutics price target lowered to $10 from $18 at Oppenheimer - TipRanks
Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks - Yahoo Finance
H.C. Wainwright maintains Acrivon stock Buy rating, $19 target - Investing.com
HC Wainwright Has Lowered Expectations for Acrivon Therapeutics (NASDAQ:ACRV) Stock Price - Defense World
FY2029 Earnings Estimate for ACRV Issued By HC Wainwright - Defense World
Cantor Fitzgerald Reaffirms “Overweight” Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics reports Q4 EPS (60c), consensus (70c) - TipRanks
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Hard-to-Treat Endometrial Cancer - Stock Titan
0.39%
3.66%
자본화:
|
볼륨(24시간):